Location:About Us > Company News > Company News

OLYMVAX was included in the Underlying Stock List of Northbound Trading Link


Recently, SSE, SZSE and SEHK simultaneously announced the inclusion of more listed companies’ stocks into the Underlying Stock List of Northbound Trading Link, marking a further expansion of the interoperability range of stock market trading between Chinese Mainland and Hong Kong, China, and a significant increase in the convenience of foreign investors participating in the A-share market. OLYMVAX was included in the List of New Securities of Northbound Trading Link, and will be officially included in the Underlying Stock List of Northbound Trading Link from March 13, 2023.

Focusing on the research, development, production and sales of human vaccines, OLYMVAX is committed to providing innovative and effective solutions against significant health issues faced by China and the world. The Company has practiced a R&D mode of “laying equal stress on independent development and joint development”, and has set up an innovative vaccine research team with independent intellectual property rights. In more than 10 years since its establishment, the Company has launched three vaccines, with outstanding research and transformation capabilities.

In addition to the listed varieties, the Company’s AC-Hib combined vaccine has entered the production and registration stage, the Recombinant Staphylococcus Aureus Vaccine (Class 1 innovative vaccine) has entered Phase III of clinical study, and multiple innovative vaccines such as Group A Streptococcus Vaccine and Tetravalent Influenza Virus Split Vaccine (MDCK cells) are under research, forming a product pipeline of “multi-product reserve, orderly stepping and key breakthrough”.

After being included in the Underlying Stock List of Northbound Trading Link, OLYMVAX is expected to gain more market attention, further increasing the liquidity of the Company. Upholding the innovative and open corporate culture, OLYMVAX will actively promote the internationalization strategy, and continue to improve its R&D strength and broaden its vaccine technology platform, so as to reward the capital market with better performance in the future.

Previous:OLYMVAX: National Investigator...Next:Mr. Rob Donelly, Commercial Mi...